On this Learning Station, you can read and test your knowledge. Tap on a book to open its chapter list. In each chapter, you can take a quiz to test your knowledge.
To take tests, you must register with your email address or cell number. It is free to register and to take tests.
For help email email@example.com or call +27 76 657 0353.
Learning is easiest with printed books. To order printed books, email firstname.lastname@example.org or call +27 76 657 0353.
Visit bettercare.co.za for information.
Take the chapter test before and after you read this chapter.
First time? Register for free. Just enter your email or cell number and create a password.
When you have completed this unit you should be able to:
Antiretroviral treatment (ART) is the use of drugs (i.e. medicines) to treat patients with HIV infection.
Antiretroviral drugs prevent HIV from multiplying (making copies of itself) in the CD4 lymphocytes. This reduces the number of viruses in the body and, thereby, allows the damaged immune system to recover. Antiretroviral treatment results in an improvement of the clinical disease.
Antiretroviral treatment stops HIV from multiplying in the body.
The goals are to:
The main goals of antiretroviral treatment are to improve the quality of life and reduce mortality due to AIDS.
The most commonly used drugs fall into one of four classes:
These are the generic (common) names of the drugs. For each generic drug there are one or more different trade names for the same drug manufactured by different companies. This makes it difficult to remember all the trade names. Therefore, it is best to remember the generic names and only the commonly used trade names of the frequently used antiretroviral drugs. If possible, use the generic names rather than the trade names.
‘Nucs’ are generally used in pairs, e.g. TDF and FTC or AZT and 3TC. However, AZT and d4T should not be used together as they compete with each other. AZT and 3TC can be combined as Combivir. TDF is usually given with 3TC or FTC.
AZT and d4T should never be used together as they compete with one another.
Common ‘nucs’ are:
Common ‘non-nucs’ are:
‘Non-nucs’ are particularly powerful inhibitors of HIV multiplication. However, HIV rapidly becomes resistant to ‘non-nucs’ if they are used alone. Therefore, they are usually used with a pair of ‘nucs’.
The common trade name for ritonavir is Norvir. Sometimes two ‘PIs’ (protease inhibitors) are put together in a single preparation such as Aluvia (a trade name for lopinavir combined with ritonavir). Using two ‘PIs’ together allow a lower dose of both with fewer side effects. Atazanavir is also always used in combination with ritonavir, but they are given as separate tablets.
There are a large number of other ‘PIs’. They are easy to recognise as their generic names all end in ‘avir’ such as ritonavir.
Yes. The common antiretroviral drugs in all classes can be taken by mouth.
It is very important that all antiretroviral drugs are taken at the same time every day.
All antiretroviral drugs must be taken by mouth at the same time every day.
Yes. With antiretroviral treatment it is essential to use a number of drugs together. This is called multi-drug treatment. It is important to use multi-drug treatment as it is more effective and also reduces the chance of the HIV becoming resistant to the drugs. The same advantages of multi-drug therapy apply to the treatment of TB. Except for the prevention of mother-to-child transmission and post-exposure prophylaxis, single or double drug treatment of HIV infection should never be used.
Multi-drug treatment should be used to treat HIV.
Highly active antiretroviral treatment (HAART) is another name for antiretroviral treatment (ART). It is the use of multiple drugs to treat HIV infection. Three or more drugs are always used together for antiretroviral treatment.
Three or more antiretroviral drugs are always used to provide antiretroviral treatment.
Unfortunately not. However, antiretroviral treatment can dramatically improve the symptoms and clinical signs of HIV infection and allow the patient to remain healthy for many years. Antiretroviral treatment is the most important advance in the management of HIV infection. Antiretroviral treatment can change the outcome of HIV infection from a rapidly fatal disease into a manageable chronic illness.
Antiretroviral treatment is the most important advance in the management of HIV infection and has changed the course from a rapidly fatal disease into a manageable chronic illness.
The choice of which antiretroviral drugs to use can be based on either an individualised or a standardised approach. Initially an individualised approach was used where the most appropriate drugs were chosen to meet the needs of each patient. More recently a standardised approach has been used where all patients are started on the same combination, as is done with TB treatment.
The standardised approach to antiretroviral drugs is preferred.
A standardised regimen consists of a specific combination of antiretroviral drugs where the risk of drug interactions and side effects are low. The drug combination should target at least two sites in the life cycle of HIV (i.e. important stages in the viral replication).
Using combinations of antiretroviral drugs is very complicated as each combination has its own risk of drug interactions. Some drugs counteract each other (block the function of the other drug). Other drug combinations have a high risk of serious side effects. Therefore, a wide knowledge and experience of these drugs is essential if the individual approach is to be used. This ability is usually only available at antiretroviral clinics where particularly difficult management problems are referred.
This is the combination of drugs which is routinely used when patients first start antiretroviral treatment.
When treating adults with HIV infection in South Africa, the first-line combination is usually two ‘nucs’ together with a ‘non-nuc’.
The 2014 South African guidelines recommend the combination of TDF plus 3TC or FTC with efavirenz as first line treatment. Unless contraindicated, all patients, including pregnant women, should be started on this regimen which should preferably be prescribed as a once daily fixed dose combination tablet. Abacavir (ABC) can be used if there are contraindications to TDF and nevirapine can be prescribed if efavirenz is contraindicated. Some old regimes still use d4T instead of TDF. However, d4T is being phased out and should be replaced by TDF, or AZT if TDF is contraindicated.
In South Africa antiretroviral treatment is usually started with TDF, FTC and efavirenz in a single fixed dose combination tablet taken once daily in the evening.
This combination is chosen for its effectiveness and availability, few serious side effects and low cost.
Patients who fail to respond to the first-line combination, despite good adherence, are changed to a second-line combination of antiretroviral drugs.
Usually two ‘nucs’ plus a combination of two ‘PIs’. The common second-line combination in South Africa is AZT plus 3TC plus ritonavir and lopinavir together. TDF can be used instead of AZT if the failed first-line combination included AZT or d4T
The previous second-line combination of AZT, ddI and Aluvia is sometimes still used.
Therefore both the first- and second-line combinations include two ‘nucs’. However, only the first-line combination includes a ‘non-nuc’ while only the second-line combination includes ‘PIs’.
In South Africa the new second-line combination is AZT plus 3TC plus ritonavir and lopinavir together.
Sometimes changes to the first- or second-line combinations are made when there are serious side effects to only one drug in a standardised regimen e.g.
These changes (swaps) should only be made by an experienced clinician at an antiretroviral clinic and care should be taken to ensure that the patient has a suppressed viral load at the time of the one drug switch. Using individualised combinations reduces the future options of treatment.
The following questions must be considered:
|AZT||zidovudine||Retrovir||300 mg||Twice daily|
|3TC**||lamivudine||3TC||150 mg||Twice daily|
|ABC||abacavir||Viagen||300 mg||Twice daily|
|d4T||stavudine||Zerit||30 mg||Twice daily|
|NVP||nevirapine||Viramune||200 mg||Twice daily***|
|LPV/r||lopinavir/ritonavir||Aluvia||400 mg/100 mg||Twice daily|
|Atazanavir/ritonavir||atazanavir/ritonavir||Reyataz/Novir||300 mg/100 mg||Daily|
* Twice daily doses are best taken 12 hours apart e.g. 7 am and 7 pm.
** 3TC is taken as a 300 mg dose daily with EFV and TDF but as a 150 mg dose twice daily with AZT and NVP.
*** Only one tablet of nevirapine daily at night for the first two weeks of treatment.
**** Efavirenz is best taken on an empty stomach for the first few weeks.
TDF (generic name tenofovir) is a ‘nuc’ (trade name is Viread). One TDF 300 mg tablet is taken daily with or without food. TDF is usually taken at night without food. TDF may cause renal impairment, noted by an increase in serum creatinine concentration in the first few months of treatment.
Some patients on an older regime may still receive d4T (generic name stavudine). d4T is also a ‘nuc’ (trade name is Zerit). One 30 mg capsule is taken twice a day (12-hourly). Capsules can be taken with or without food. However, taking d4T with food reduces nausea. More recent guidelines do not include d4T.
d4T must not be given with ddI.
3TC is also a ‘nuc’ (generic name is lamivudine while trade name is also 3TC). One 150 mg tablet is taken twice a day (12-hourly) with or without food. However, 300 mg 3TC may be taken as a once-daily dose. 3TC is well tolerated and has very few side effects. Mild nausea, headache and diarrhoea may occur.
3TC is well tolerated with few side effects.
AZT (generic name zidovudine) is a ‘nuc’ (trade name is Retrovir). One 300 mg tablet is taken twice daily (12-hourly). Tablets can be taken with or without food. However, nausea may be less if taken with food. AZT has many short term minor side effects such as fatigue, nausea and vomiting, headache, muscle pains and altered taste. These are common at the start of treatment and are worse with higher doses. However, they become less after a few weeks. AZT may also discolour the nails.
The most important side effect of AZT is anaemia. This usually occurs in the first few months of treatment.
AZT may cause anaemia.
ABC (generic name abacavir) is also a ‘nuc’ (trade name is Viagen). ABC 300mg (1 tablet) should be taken every 12 hours. ABC is usually used if a patient cannot take TDF. ABC is well-tolerated though there is a small risk of a severe initial hypersensitivity reaction.
Nevirapine is a ‘non-nuc’. One nevirapine 200 mg tablet (trade name is Viramune) is taken at night to start with. After 14 days the dosage is increased to one tablet twice daily (12-hourly). If there is a mild rash or raised liver enzymes, do not increase the dose to twice a day until the liver enzymes have dropped and the rash has cleared.
A mild rash is common, usually during the first six weeks of treatment. A severe rash may also occur with nevirapine. The drugs must be stopped immediately if a severe rash appears.
Nevirapine may cause early, serious side effects.
Efavirenz is also a ‘non-nuc’ and is very similar to nevirapine.
One efavirenz 600 mg capsule (trade name Stocrin) is taken at night. Efavirenz has the advantage of the patient only needing a single dose a day.
A rash may occur. However this side effect is less common and not always as severe as with nevirapine. Efavirenz commonly causes mild emotional symptoms for the first few weeks (mood changes, abnormal dreams, insomnia and dizziness). These are reduced if efavirenz is taken on an empty stomach in the evening. When side effects have cleared efavirenz should be taken with meals.
Initially, efavirenz was avoided during the first trimester of pregnancy, as it was thought to cause fetal abnormalities (birth defects). Subsequent data has shown no increase in fetal abnormalities with efavirenz and current guidelines allow the use of efavirenz throughout pregnancy.
Efavirenz is thought to be safe in a woman who is at risk of falling pregnant.
Usually lopinavir 400 mg and ritonavir 100 mg (LPV/r) are taken in combination as Aluvia. Two tablets of Aluvia are taken twice a day (12-hourly) with or without food. Nausea and diarrhoea are common for the first few weeks. These side effects can be reduced if the drug is taken with food. Due to drug interactions, the dosages of many drugs have to be altered if they are used together with lopinavir and ritonavir.
Atazanavir 300mg is usually taken with ritonavir 100mg, both once a day. Atazanavir is usually better tolerated than lopinavir. Patients may present with jaundice, due to an increase in unconjugated bilirubin. Liver functions will be normal. This jaundice is harmless and the atazanavir can be continued.
The dose of lopinavir/ritonavir must be increased if used with efavirenz or rifampicin. Atazanavir/ritonavir cannot be used with rifampicin.
It is important that ddI is taken on an empty stomach as food decreases the absorption of the drug. In addition, the side effects of efavirenz are less if the drug is taken on an empty stomach in the evenings. Therefore it is best if efavirenz is taken without food for the first few weeks. However, most other antiretroviral drugs can be taken once a day with meals.
Only ddI must be taken on an empty stomach.
If the previous second-line combination is used, AZT and lopinavir/ritonavir are best taken with meals, but ddI must be taken on an empty stomach. Take ddI at least an hour before or two hours after a meal.
It is important to know which drugs should be taken with meals and which drugs must be taken on an empty stomach.
The antiretroviral drugs currently used do not need to be kept in a fridge.
Side effects to antiretroviral drugs are common and usually mild, but they can sometimes be severe. Remember that drugs used to treat HIV-associated infections also cause side effects, which may be similar to the clinical symptoms and signs of HIV infection. Most side effects can be easily managed.
Side effects can be graded into mild (grade 1), moderate (grade 2), severe (grade 3) and potentially life threatening (grade 4).
All antiretroviral drugs may have side effects.
It is very important that patients know the common side effects of the antiretroviral drugs that they are taking. It is also important that patients know which side effects to look out for and which can be serious. If side effects are mild, patients should not stop the antiretroviral drugs. With severe side effects they should report immediately to the clinic. Educating patients about side effects is an important part of care. All patients on antiretroviral treatment must be able to monitor themselves for side effects.
Patients should be educated about side effects.
Tiredness, nausea and vomiting, headaches and diarrhoea are common and may be caused by all classes of antiretroviral drugs. These side effects are not serious and usually settle after the first few days or weeks. It is important that patients continue with their antiretroviral drugs in spite of mild side effects. Sometimes other medication can be taken to help relieve these symptoms (paracetamol for headache and antiemetics for nausea and vomiting). Taking antiretroviral treatment with food often helps reduce side effects. Side effects, no matter how mild, must always be reported to the staff. Fortunately, most side effects are mild. Most patients will not experience side effects.
Most patients experience no side effects.
Name of drug
Major side effects
Renal failure, rash, fractures
Few side effects
Nausea and vomiting, anaemia, neutropenia
Peripheral neuropathy, pancreatitis, lactic acidosis, lipodystrophy
Peripheral neuropathy, pancreatitis, lactic acidosis, lipodystrophy
Severe rash, hepatitis
Emotional or psychiatric symptoms, rash
Most side effects occur in the first six weeks of starting antiretroviral treatment. They usually get better on their own after one to two months. However, some serious side effects may occur at any time that antiretroviral drugs are taken.
Rashes are common with antiretroviral treatment and usually are caused by ‘non-nucs’, especially nevirapine. TDF may also cause a rash. These rashes almost always occur in the first six weeks of treatment.
Nevirapine and efavirenz commonly cause skin rashes.
Remember that HIV infection itself and drugs used to treat HIV-associated infections (especially co-trimoxazole) also commonly causes rashes. Therefore the rash may not be due to the antiretroviral drugs.
Nevirapine must always be started at half doses (i.e. 200 mg once daily) for the first 14 days as this reduces the risk of a rash. Continue treatment if the rash is mild. Do not increase the dose of nevirapine until any rash has settled.
All patients with a severe rash must be referred to an antiretroviral clinic urgently. If this cannot be done on the same day, stop all three antiretroviral drugs immediately and send the patient to an antiretroviral clinic as soon as possible. Usually nevirapine is swapped for a ‘PI’. These patients must never be given a ‘non-nuc’ again (i.e. neither nevirapine nor efavirenz should ever be prescribed again).
All antiretroviral drugs must be stopped immediately if a severe rash occurs.
All classes of antiretroviral drugs can cause hepatitis. However, nevirapine is the drug which is usually associated with hepatitis. Efavirenz can also cause hepatitis but less commonly.
Hepatitis due to nevirapine is most common in patients, especially women, who have a high CD4 count before the start of treatment.
Liver function tests (ALT, i.e. alanine amino transferase) should be done on all patients when nevirapine is started and also should be checked if a patient on efavirenz or nevirapine develops a rash or symptoms of hepatitis.
Hepatitis is usually caused by nevirapine.
Hepatitis may be clinical (nausea, loss of appetite, jaundice, enlarged liver, itching and abdominal pain) or asymptomatic (when it is diagnosed by finding raised liver enzymes in the blood without any clinical signs of hepatitis). An ALT level above three times normal (normal below 40 iu/l) indicates an increased risk of hepatitis.
Patients with asymptomatic hepatitis and only mildly raised liver enzymes (up to five times normal) can be followed clinically without stopping the drugs. The hepatitis usually resolves. Using a low dose of nevirapine (200 mg daily) for the first two weeks lowers the risk of hepatitis (and rash).
Patients with clinical hepatitis or asymptomatic hepatitis with markedly raised liver enzymes should be urgently referred to an antiretroviral clinic where stopping all treatment may be considered.
Anaemia (Hb below 10 g/dl) is seen in few patients receiving AZT. These patients may appear pale and feel weak and dizzy. Anaemia is usually mild and the AZT need not be stopped.
A haemoglobin level and differential count or full blood count should be done when AZT is started and should be repeated at four weeks, eight weeks, 12 weeks and 24 weeks. Patients with a haemoglobin level below 8 g/dl due to AZT should have the AZT dose reduced or should swap the AZT for another NRTI.
Anaemia is a side effect of AZT.
This is a problem which affects the peripheral nerves, especially in the legs. It presents with pain, numbness and abnormal sensation in a ‘glove and stocking’ distribution. Most patients with peripheral neuropathy present with painful feet at night.
Peripheral neuropathy is usually caused by ‘nucs’ which have a ‘d’ in their names, e.g. ddI and d4T. These drugs should not be used together as this increases the risk of peripheral neuropathy. Depending on the severity of the neuropathy, the drugs may have to be changed, after consultation with an HIV clinic, as the peripheral neuropathy can become worse if the drug is continued. The symptoms of peripheral neuropathy usually slowly improve after the drugs have been stopped. Other drugs, such as INH and alcohol may also cause peripheral neuropathy.
d4T and ddI are associated with peripheral neuropathy and should not be used together.
Lipodystrophy is an abnormal distribution of subcutaneous fat resulting in a change in body shape (fat redistribution syndrome). Fat is lost (lipoatrophy) from the face and limbs and gained (accumulated) over the abdomen, back of the neck and breasts. Unfortunately lipodystrophy is not usually corrected when the antiretroviral drugs are changed. Many patients gain weight when antiretroviral treatment is started. Lipodystrophy is usually caused by ddI, d4T, efavirenz, AZT and the PIs.
Lipodystrophy is a redistribution in body fat and is usually associated with d4T and ddI and the PIs.
Lactic acidosis is a rare but serious and potentially fatal side effect of ‘nucs’, particularly d4T and ddI. Therefore these drugs must never be used together. It usually only occurs more than six months into treatment when patients have responded well and are clinically improving with good adherence. It is most common in women who are overweight or pregnant. Patients with lactic acidosis present with a gradual onset of tiredness, weight loss and abdominal complaints (nausea, vomiting, abdominal pain or discomfort). Always suspect lactic acidosis if patients, who have been well and gaining weight for months, start to lose weight. Lactic acidosis has become a rare side effect of ART since the introduction of TDF in first line treatment instead of d4T.
Lactic acidosis is a rare but serious side effect of ‘nucs’ and occurs after months of good response to treatment.
Patients with suspected lactic acidosis must be immediately taken off all treatment and urgently referred to an HIV treatment centre for investigation and management.
Pancreatitis (inflammation of the pancreas) is another severe complication of d4T and ddI, especially when they are used together. Alcohol abuse may increase the risk of pancreatitis.
Pancreatitis presents with vomiting, abdominal pain and tenderness. The drugs must be stopped immediately and the patient urgently referred.
Abdominal pain or discomfort is an important symptom in patients on antiretroviral treatment as it may be due to hepatitis, lactic acidosis or pancreatitis.
Some antiretroviral drugs cause nausea and vomiting or diarrhoea. The problem is usually mild and settles after a few weeks. However, vomiting may be severe (especially with AZT) while diarrhoea may also be severe (especially with Aluvia). This can lead to dehydration. Taking medicine with food and anti-nausea medication may help reduce vomiting. Efavirenz should be taken without food if it causes vomiting.
Oral rehydration solution will help prevent or correct dehydration. Patients with signs of severe dehydration should be urgently referred to hospital.
No. Antiretroviral drugs are a very important part in the treatment of HIV infection and the only way of managing AIDS. Like most other drugs, they have side effects. Usually side effects are mild and the antiretroviral drugs need not be stopped. Most patients have no or only mild side effects. However, both patients and health workers should know the symptoms and signs of severe side effects. If these appear the drugs must be stopped immediately and the patient referred urgently to an antiretroviral clinic for assessment.
The advantages of antiretroviral drugs far outweigh the side effects.
Minor side effects are common, e.g. nausea, vomiting, diarrhoea, headaches, muscle pains, sleeplessness, minor rashes. However, serious side effects such as serious rashes and hepatitis may also occur early and need to be looked out for.
Most minor side effects during the initiation of antiretroviral treatment get better over time without any treatment.
Peripheral neuropathy may also occur early in treatment.
Normally patients feel better and gain weight when antiretroviral treatment is started. Therefore weight loss on antiretroviral treatment is an important danger sign. It may be due to common early side effects such as nausea, vomiting or diarrhoea. However, weight loss in patients who have previously been well may also indicate the development of lactic acidosis.
Many patients on antiretroviral treatment complain of hunger once their immune system starts to recover. This may be a problem in poor people who cannot afford to buy more food.
It may be necessary to stop an antiretroviral drug if severe side effects occur, e.g. severe rash or clinical hepatitis. If this is done, all drugs must be stopped together. Stopping one drug will lead to resistance of the remaining two drugs. The drug combination must be carefully examined as the problem drug may have to be swapped or a different combination may be needed. Changing drugs must always be done at an antiretroviral clinic by an HIV expert. HIV infection must never be treated with only one or two drugs. A full combination of three drugs is always needed.
If necessary, stop all antiretroviral drugs and not just one drug.
Most antiretrovirals are safe in pregnancy. Previous anxiety about Efavirenz causing congenital malformations (birth defects) appears to be unfounded.
TDF can cause renal damage, which presents as a drop in creatinine clearance. Therefore creatinine clearance should be monitored at one month, three or four months, six months and then 12-monthly thereafter, when the drug is used. Do not use TDF if the creatinine clearance is less than 50 ml/min.
TDF can cause kidney damage.
A patient with HIV infection, who has been treated with AZT alone for two weeks by a general practitioner, is referred to an HIV clinic. The patient complains of headache, nausea and feeling generally unwell since the treatment was started.
No. One or two drugs alone should never be used to treat HIV. Three drugs are always used together (multi-drug therapy), e.g. AZT, 3TC and lopinavir/ritonavir.
There is a higher rate of successful treatment with less drug resistance.
These are common side effects of AZT. Mild side effects of antiretroviral treatment usually settle on their own after a few weeks. Unless the side effects are serious, treatment should not be stopped. Mild side effects can be treated symptomatically.
Anaemia. Therefore the haemoglobin concentration should be monitored in patients receiving antiretroviral treatment which includes AZT.
TDF, AZT, 3TC, d4T, ABC and ddI are ‘nucs’. They all block an important enzyme and thereby prevent HIV from infecting CD4 lymphocytes. ‘Nucs’ are used in most multi-drug regimens to treat HIV.
To suppress the multiplication of HIV. This will allow the immune system to recover (increased CD4 count), improve the patient’s clinical condition and decrease the risk of death.
A young woman who has HIV infection presents at an HIV clinic with the hope of being cured. She wants to start a family as soon as she is well again.
Unfortunately not. However, it can markedly improve the patient’s health and make HIV infection a chronic but manageable disease.
She should be given a standardised regimen. Once she has been prepared for treatment, a first-line combination of TDF, FTC and efavirenz will be started.
This is a fixed combination of antiretroviral drugs. There are many advantages to a standardised regimen over an individualised regimen. With an individualised regimen each patient is given their own combination of antiretroviral drugs.
It is simpler, safer and cheaper to use with fewer side effects and drug interactions. The education and training of both patients and staff is much easier. Tuberculosis is also treated with a standardised fixed combination of drugs.
The first line regimen of choice is TDF plus FTC and efavirenz as a once daily combination tablet.
Other first line regimens are:
Efavirenz is the ‘non-nuc’ of choice, particularly if her CD4 count is above 250cells/µl as people with high CD4 cell counts have an increased risk of hepatitis when starting nevirapine.
A patient has recently started on a first-line regimen with nevirapine. Three weeks after starting antiretroviral treatment he develops a fever and feels ill with a generalised blistering skin rash which also involves his mouth.
Yes. They are usually mild and the patient does not feel generally unwell. With continued antiretroviral treatment most mild skin rashes caused by nevirapine will disappear.
Yes, because this is a serious rash and the patient is ill with a fever. Any blistering skin rash, especially if it involves the mouth, is potentially life threatening. All drugs must be stopped immediately and the patient should be referred urgently to hospital. Nevirapine will have to be replaced (swapped) with a ‘PI’ such as Aluvia.
No. This patient must never again be given a ‘non-nuc’ (either nevirapine or efavirenz) as the severe reaction is likely to recur.
Hepatitis. Clinical hepatitis presents with nausea and vomiting, abdominal pain and jaundice. A rash and hepatitis may occur together. Patients with any signs of hepatitis must be urgently referred to hospital. Severe hepatitis can be fatal.
By starting with a smaller dose for the first two weeks of treatment (one tablet at night only).
It is very important that patients be well educated about the symptoms and signs of the common side effects before antiretroviral treatment starts. They should immediately report any side effects.
During preparation for antiretroviral treatment a group of patients is fully informed about the drugs they are going to take. One patient is afraid of starting treatment when he learns about the possible side effects. A friend of his developed very painful legs after antiretroviral treatment was started.
They must know the names and appearances of the drugs in the first-line combination. They must know how many drugs to take and when they should be taken.
Some drugs (e.g. AZT and 3TC) are taken twice a day (12-hourly) while TDF and Efavirenz are taken once a day. Some formulations of 3TC also allow once daily dosing. Nevirapine is taken once a day to start, but later is also taken twice a day.
Most antiretroviral drugs in the first-line combination should be taken with meals as this reduces the risk of side effects. For the first few weeks efavirenz should be taken on an empty stomach. Second-line drugs are also taken with meals.
No. Antiretroviral drugs are the only way to effectively treat patients with HIV. Without antiretroviral treatment they will die. Most patients have no or only mild side effects.
Pain and numbness of the hands and feet are due to peripheral neuropathy. This is usually caused by d4T or ddI. Therefore, these two drugs should never be used together as this increases the risk of peripheral neuropathy. Other drugs such as INH and alcohol may also cause peripheral neuropathy.
After failing treatment with the first-line combination of antiretroviral treatment, a patient is started on the second-line combination. She feels much better on the new treatment. However, after a few months she notices that her face is becoming wasted and she is gaining weight around her abdomen.
This depends on the first line regimen but the usual combination is AZT and 3TC plus lopinavir/ritonavir.
AZT and 3TC are ‘nucs’. As with the first-line combination, ‘nucs’ are an important part of the multi-drug regimen. Aluvia is a combination of two ‘PIs’ (ritonavir and lopinavir). The second-line combination therefore includes ‘PIs’ but not ‘non-nucs’.
Twice a day with meals.
Nausea and loose stools. These are less troublesome if the medication is taken with meals.
Unfortunately peripheral wasting of the face and limbs and central fat accumulation over the stomach and back of the neck may occur with AZT and the ‘PIs’. This change of body shape due to the redistribution of fat does not always resolve if these drugs are stopped.